Immunomedics, Inc. (IMMU) EPS Estimated At $-0.20

August 14, 2018 - By Kristen Paramore

Immunomedics, Inc. (NASDAQ:IMMU) LogoInvestors sentiment increased to 1.26 in 2018 Q1. Its up 0.19, from 1.07 in 2017Q4. It increased, as 15 investors sold Immunomedics, Inc. shares while 46 reduced holdings. 26 funds opened positions while 51 raised stakes. 117.56 million shares or 0.32% more from 117.18 million shares in 2017Q4 were reported.
Jgp Global Gestao De Recursos Ltda reported 0.09% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Proshare Lc has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Point72 Asset Mgmt Limited Partnership owns 0.03% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 449,220 shares. Advisory Services Networks Limited Com invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Guggenheim Capital Limited Co has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 185,415 shares. Jpmorgan Chase & invested in 0% or 23,091 shares. Morgan Stanley owns 527,197 shares. Sphera Funds Mngmt Limited owns 480,000 shares or 1.06% of their US portfolio. Spectrum Mngmt Group Inc accumulated 2,500 shares. 302,898 were reported by Alliancebernstein Ltd Partnership. Goldman Sachs Gp invested in 594,252 shares or 0% of the stock. Swiss Commercial Bank has 211,650 shares for 0% of their portfolio. Pictet Asset Management Ltd has 1.60 million shares for 0.06% of their portfolio. Prudential Fincl Inc has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Shaker Invs Limited Oh holds 0.24% or 26,400 shares.

Since February 28, 2018, it had 2 insider purchases, and 1 sale for $16.43 million activity. GOLDENBERG DAVID M had sold 117,729 shares worth $2.05 million.

Analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report $-0.20 EPS on August, 15.They anticipate $0.05 EPS change or 20.00 % from last quarter’s $-0.25 EPS. After having $-0.14 EPS previously, Immunomedics, Inc.’s analysts see 42.86 % EPS growth. The stock decreased 3.68% or $0.87 during the last trading session, reaching $22.74. About 979,061 shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 204.95% since August 14, 2017 and is uptrending. It has outperformed by 192.38% the S&P500.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 2 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 3 analyst reports since May 17, 2018 according to SRatingsIntel. As per Monday, June 4, the company rating was maintained by Wells Fargo. As per Thursday, May 17, the company rating was maintained by Wells Fargo. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Wednesday, June 6 by FBR Capital.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $4.10 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

More recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Seekingalpha.com which released: “Immunomedics announces multiple collaborations with cancer research institutions” on July 30, 2018. Also Globenewswire.com published the news titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph …” on August 10, 2018. Nasdaq.com‘s news article titled: “Cannabis Firm To Debut On Nasdaq Today, CTIC Plunges, IMMU To Face FDA In Jan” with publication date: July 19, 2018 was also an interesting one.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: